Phio Pharmaceuticals Corp Stock Analysis

PHIO Stock  USD 0.69  0.02  2.82%   
Phio Pharmaceuticals Corp is undervalued with Real Value of 18.5 and Target Price of 72.0. The main objective of Phio Pharmaceuticals stock analysis is to determine its intrinsic value, which is an estimate of what Phio Pharmaceuticals Corp is worth, separate from its market price. There are two main types of Phio Pharmaceuticals' stock analysis: fundamental analysis and technical analysis.
The Phio Pharmaceuticals stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Phio Pharmaceuticals is usually not traded on Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day, Labour Day, Thanksgiving Day. Phio Stock trading window is adjusted to America/New York timezone.
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Phio Pharmaceuticals Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

Phio Stock Analysis Notes

The company has price-to-book ratio of 0.4. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Phio Pharmaceuticals Corp recorded a loss per share of 2.52. The entity last dividend was issued on the 15th of January 2020. The firm had 1:12 split on the 26th of January 2023. Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. Phio Pharmaceuticals Corp. was incorporated in 2011 and is headquartered in Marlborough, Massachusetts. Phio Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 12 people. To find out more about Phio Pharmaceuticals Corp contact the company at 508 767 3861 or learn more at

Phio Pharmaceuticals Corp Investment Alerts

Phio Pharmaceuticals had very high historical volatility over the last 90 days
Phio Pharmaceuticals has some characteristics of a very speculative penny stock
Net Loss for the year was (10.83 M) with loss before overhead, payroll, taxes, and interest of (7.01 M).
Phio Pharmaceuticals Corp currently holds about 18.02 M in cash with (10.75 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.32, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Phio Pharmaceuticals has a frail financial position based on the latest SEC disclosures
Latest headline from Phio Pharmaceuticals Announces New Patent for INTASYL Compound That Targets Photo-aging

Phio Pharmaceuticals Corp Upcoming and Recent Events

Earnings reports are used by Phio Pharmaceuticals to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period..
27th of March 2024
Upcoming Quarterly Report
9th of May 2024
Next Financial Report
31st of December 2023
Next Fiscal Quarter End
27th of March 2024
Next Fiscal Year End
30th of September 2023
Last Quarter Report
31st of December 2022
Last Financial Announcement

Phio Largest EPS Surprises

Earnings surprises can significantly impact Phio Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Fiscal Date
Estimated EPS
Reported EPS
View All Earnings Estimates

Phio Stock Institutional Investors

Blackrock Inc2024-03-31
Sabby Management Llc2024-03-31
Citigroup Inc2023-12-31
Renaissance Technologies Corp2024-03-31
Morgan Stanley - Brokerage Accounts2024-03-31
Anson Funds Management Lp2024-03-31
Geode Capital Management, Llc2023-12-31
Jpmorgan Chase & Co2023-12-31
Virtu Financial Llc2024-03-31
30.9 K
Cetera Advisors Llc2024-03-31
30.4 K
Cetera Investment Advisers2024-03-31
30.4 K
Note, although Phio Pharmaceuticals' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Phio Market Capitalization

The company currently falls under 'Nano-Cap' category with a current market capitalization of 3.27 M.

Phio Profitablity

Last ReportedProjected for Next Year
Return On Tangible Assets(1.16)(1.21)
Return On Capital Employed(1.38)(1.31)
Return On Assets(1.16)(1.21)
Return On Equity(1.40)(1.33)

Management Efficiency

Phio Pharmaceuticals Corp has return on total asset (ROA) of (0.6965) % which means that it has lost $0.6965 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.4523) %, meaning that it created substantial loss on money invested by shareholders. Phio Pharmaceuticals' management efficiency ratios could be used to measure how well Phio Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of the 22nd of June 2024, Return On Tangible Assets is likely to drop to -1.21. In addition to that, Return On Capital Employed is likely to grow to -1.31. At this time, Phio Pharmaceuticals' Total Assets are very stable compared to the past year. As of the 22nd of June 2024, Total Current Assets is likely to grow to about 12.1 M, while Non Current Assets Total are likely to drop about 39.9 K.
Last ReportedProjected for Next Year
Book Value Per Share 3.71  3.52 
Tangible Book Value Per Share 3.71  3.52 
Enterprise Value Over EBITDA 0.65  0.69 
Price Book Value Ratio 0.20  0.19 
Enterprise Value Multiple 0.65  0.69 
Price Fair Value 0.20  0.19 
Enterprise Value-6.9 M-7.2 M
The analysis of Phio Pharmaceuticals' management efficiency is an essential part of evaluating and assessing the financial and operational performance of the entity. It is also vital to analyze Phio Pharmaceuticals' future growth prospects and the overall market conditions to determine the value and potential of its stock. The analysis involves studying a range of financial metrics such as revenue, earnings, profit margins, cash flow, debt, market share, and external factors such as economic trends, industry outlook, competition, and government regulations. The goal of Phio Stock analysis is to determine whether it is undervalued, fairly valued, or overvalued and to make informed investment decisions.
Return On Assets
Return On Equity

Technical Drivers

As of the 22nd of June, Phio Pharmaceuticals holds the Coefficient Of Variation of (2,432), risk adjusted performance of (0.02), and Variance of 44.04. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Phio Pharmaceuticals, as well as the relationship between them.

Phio Pharmaceuticals Corp Price Movement Analysis

Execute Study
The output start index for this execution was twenty-three with a total number of output elements of thirty-eight. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Phio Pharmaceuticals middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Phio Pharmaceuticals Corp. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.

Phio Pharmaceuticals Corp Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Phio Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Phio Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Phio Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Robert Bitterman over two weeks ago
Acquisition by Robert Bitterman of 1000 shares of Phio Pharmaceuticals at 0.74 subject to Rule 16b-3
Robert Bitterman over two weeks ago
Acquisition by Robert Bitterman of 1000 shares of Phio Pharmaceuticals at 0.75 subject to Rule 16b-3
Robert Bitterman over a month ago
Acquisition by Robert Bitterman of 40000 shares of Phio Pharmaceuticals subject to Rule 16b-3
Robert Bitterman over two months ago
Acquisition by Robert Bitterman of 2000 shares of Phio Pharmaceuticals at 0. subject to Rule 16b-3
Robert Bitterman over two months ago
Acquisition by Robert Bitterman of 300000 shares of Phio Pharmaceuticals at 0.1 subject to Rule 16b-3
Robert Bitterman over three months ago
Acquisition by Robert Bitterman of 2500 shares of Phio Pharmaceuticals at 0.91 subject to Rule 16b-3
Robert Bitterman over three months ago
Disposition of 1804 shares by Robert Bitterman of Phio Pharmaceuticals at 0.76 subject to Rule 16b-3
Caitlin Kontulis over three months ago
Disposition of 523 shares by Caitlin Kontulis of Phio Pharmaceuticals at 0.66 subject to Rule 16b-3
Caitlin Kontulis over three months ago
Disposition of 658 shares by Caitlin Kontulis of Phio Pharmaceuticals at 0.65 subject to Rule 16b-3
Caitlin Kontulis over six months ago
Payment of 335 shares by Caitlin Kontulis of Phio Pharmaceuticals subject to Rule 16b-3
Ferrara Robert L over a year ago
Purchase by Ferrara Robert L of 2000 shares of Phio Pharmaceuticals
Caitlin Kontulis over a year ago
Payment of 335 shares by Caitlin Kontulis of Phio Pharmaceuticals subject to Rule 16b-3

Phio Pharmaceuticals Predictive Daily Indicators

Phio Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Phio Pharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Phio Pharmaceuticals Forecast Models

Phio Pharmaceuticals' time-series forecasting models are one of many Phio Pharmaceuticals' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Phio Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Phio Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Phio Pharmaceuticals prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Phio shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Phio Pharmaceuticals. By using and applying Phio Stock analysis, traders can create a robust methodology for identifying Phio entry and exit points for their positions.
Last ReportedProjected for Next Year
Pretax Profit Margin(487.82)(512.21)
Operating Profit Margin(492.15)(516.75)
Net Loss(61.33)(64.40)
Gross Profit Margin 0.72  0.75 

Current Phio Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Phio analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Phio analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
Phio Pharmaceuticals Corp current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Phio analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Phio stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Phio Pharmaceuticals Corp, talking to its executives and customers, or listening to Phio conference calls.
Phio Analyst Advice Details

Phio Stock Analysis Indicators

Phio Pharmaceuticals Corp stock analysis indicators help investors evaluate how Phio Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Phio Pharmaceuticals shares will generate the highest return on investment. By understating and applying Phio Pharmaceuticals stock analysis, traders can identify Phio Pharmaceuticals position entry and exit signals to maximize returns.
Begin Period Cash Flow11.8 M
Common Stock Shares Outstanding2.1 M
Total Stockholder Equity7.7 M
Property Plant And Equipment Net39 K
Cash And Short Term Investments8.5 M
Cash8.5 M
Accounts Payable657 K
Net Debt-8.5 M
50 Day M A0.7357
Total Current Liabilities1.6 M
Other Operating Expenses10.7 M
Non Current Assets Total42 K
Forward Price Earnings0.3064
Non Currrent Assets Other3000.00
Stock Based Compensation303 K

Additional Information and Resources on Investing in Phio Stock

When determining whether Phio Pharmaceuticals Corp offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Phio Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Phio Pharmaceuticals Corp Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Phio Pharmaceuticals Corp Stock:
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Phio Pharmaceuticals Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.
You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Phio Pharmaceuticals. If investors know Phio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Phio Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
Return On Assets
Return On Equity
The market value of Phio Pharmaceuticals Corp is measured differently than its book value, which is the value of Phio that is recorded on the company's balance sheet. Investors also form their own opinion of Phio Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Phio Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Phio Pharmaceuticals' market value can be influenced by many factors that don't directly affect Phio Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Phio Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Phio Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Phio Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.